Keyphrases
Phase I Study
100%
Temozolomide
100%
Advanced Cancer
100%
Thalidomide
100%
Capecitabine
100%
Dose-limiting Toxicity
80%
Dose Level
40%
Neutropenia
20%
Adult Patients
20%
Prostate
20%
Colon
20%
Pancreas
20%
Partial Response
20%
Dose Interruption
20%
Phase II Trial
20%
Antiangiogenic
20%
Stable Disease
20%
Long-term Treatment
20%
Chemotherapy Regimen
20%
Clinical Benefit
20%
Metastatic Cancer
20%
Immunomodulatory
20%
Recommended Dose
20%
Patients with Advanced Cancer
20%
Fixed-dose Combination
20%
One-at-a-time
20%
Hand-foot Syndrome
20%
Chemoimmunotherapy
20%
Phase I Design
20%
Pharmacology, Toxicology and Pharmaceutical Science
Temozolomide
100%
Advanced Cancer
100%
Thalidomide
100%
Capecitabine
100%
Neutropenia
20%
Chemotherapy
20%
Immunotherapy
20%
Phase II Trials
20%
Metastasis
20%
Antiangiogenic
20%
Kidney Disease
20%
Hand Foot Syndrome
20%